US 2015/0297618 A1 - Methods Of Treating Acne - The Lens - Free & Open Patent and Scholarly Search

Patents

US 2015/0297618 A1

Methods Of Treating Acne

Published: Oct 22, 2015
Earliest Priority: Apr 05 2001
Family: 18
Cited Works: 0
Cited by: 0
Cites: 0
Additional Info: Full text

Abstract

A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.

Claims

A method for treating acne in a human in need thereof, the method comprising
administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof,

in an amount that

(i) is effective to treat acne;

(ii) is 10-80% of a 50 mg dose of doxycycline; and

(iii) results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.
The method according to claim 1, wherein said doxycycline is doxycycline monohydrate.
The method according to claim 2, wherein said doxycycline monohydrate is administered in an amount of 40 milligrams.
The method according to claim 3, wherein said doxycycline monohydrate is administered by sustained release.
A method according to claim 4, wherein said doxycycline monohydrate is administered once a day.
The method according to claim 2, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.
The method according to claim 1, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 μg/ml.
A method for treating acne in a human in need thereof, the method comprising
administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof,

in an amount that

(i) is effective to treat acne;

(ii) is 40-80% of a 50 mg dose of doxycycline; and

(iii) results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.
The method according to claim 8, wherein said doxycycline is doxycycline monohydrate.
The method according to claim 9, wherein said doxycycline monohydrate is administered in an amount of 40 milligrams.
The method according to claim 10, wherein said doxycycline monohydrate is administered by sustained release.
A method according to claim 11, wherein said doxycycline monohydrate is administered once a day.
The method according to claim 9, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.
The method according to claim 8, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 μg/ml.
A method for treating acne in a human in need thereof, the method comprising
administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof, in an amount of 40 mg per day, wherein the amount results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.
The method according to claim 15, wherein said doxycycline is doxycycline monohydrate.
The method according to claim 16, wherein said doxycycline monohydrate is administered by sustained release.
A method according to claim 17, wherein said doxycycline monohydrate is administered once a day.
The method according to claim 16, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.
The method according to claim 15, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 μg/ml.

Owners (US)

Galderma Labortories Inc (Jul 29 2008)
Explore more patents:
- View all patents where Owners (US) GALDERMA LABORTORIES INC
Collagenex Pharmaceuticals Inc (Jul 20 2002)
Explore more patents:
- View all patents where Owners (US) COLLAGENEX PHARMACEUTICALS INC

Applicants

Galderma Lab Inc
Explore more patents:
- View all patents where Applicants GALDERMA LAB INC

Inventors

Ashley Robert A
Explore more patents:
- View all patents where Inventors ASHLEY ROBERT A
- View all scholarly literature where Author = ASHLEY ROBERT A

CPC Classifications

A61K31/135
Explore more patents:
- View all patents where CPC Classifications A61K31/135
- View in Classification Explorer
A61K31/65
Explore more patents:
- View all patents where CPC Classifications A61K31/65
- View in Classification Explorer
A61K9/0053
Explore more patents:
- View all patents where CPC Classifications A61K9/0053
- View in Classification Explorer
D06M16/00
Explore more patents:
- View all patents where CPC Classifications D06M16/00
- View in Classification Explorer

IPC Classifications

A61K31/65
Explore more patents:
- View all patents where IPC Classifications A61K31/65
- View in Classification Explorer

Download PDF

Document Preview

Document History

Publication: Oct 22, 2015
US 2015/0297618 A1
Application: Jun 29, 2015
US 201514753544 A
Priority: Jun 29, 2015
US 201514753544 A
Priority: Dec 9, 2013
US 201314101030 A
Priority: Mar 15, 2013
US 201313838559 A
Priority: Oct 20, 2011
US 201113277789 A
Priority: Oct 22, 2007
US 87647807 A
Priority: Jan 14, 2004
US 75765604 A
Priority: Apr 5, 2002
US 11770902 A
Priority: Sep 26, 2001
US 32548901 P
Priority: Apr 5, 2001
US 28191601 P